EGFR and glioblastoma: Thus, caveolin-1 interaction may be one mechanism in which EGFR-targeted therapies inhibit kinase activity, however, GBM cell survival is likely to continue due to stabilisation of EGFR expression and the presence of a now inactive, KID-EGFR.